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Interoceptive conditioning with nicotine using extinction and re-
extinction to assess stimulus similarity with bupropion
Sergios Charntikov, Nicole R. deWit, and Rick A Bevins*
Department of Psychology, 238 Burnett Hall, University of Nebraska-Lincoln, Lincoln, NE
68588-0308, USA
Abstract
Bupropion is an atypical antidepressant that increases long-term quit rates of tobacco smokers. A
better understanding of the relation between nicotine and this first-line medication may provide
insight into improving treatment. For all experiments, rats first had nicotine (0.4 mg base/kg) and
saline session intermixed; intermittent access to sucrose only occurred on nicotine session.
Nicotine in this protocol comes to differentially control “anticipatory” dipper entries. To more
closely examine the overlap in the interoceptive stimulus effects of nicotine and bupropion, we
assessed whether subsequent prolonged and repeated non-reinforced (extinction) sessions with the
bupropion stimulus could weaken responding to nicotine (i.e., transfer of extinction). We also
examined whether retraining the discrimination after initial extinction and then conducting
extinction again (i.e., re-extinction) with bupropion would affect responding. We found that
bupropion (20 and 30 mg/kg) fully substituted for the nicotine stimulus in repeated 20-min
extinction sessions. The extent of substitution in extinction did not necessarily predict
performance in the transfer test (e.g., nicotine responding unchanged after extinction with 20
mg/kg bupropion). Generalization of extinction back to nicotine was not seen with 20 mg/kg
bupropion even after increasing the number of extinction session from 6 to 24. Finally, there was
evidence that learning in the initial extinction phase was retained in the re-extinction phase for
nicotine and bupropion. These findings indicate that learning involving the nicotine stimuli are
complex and that assessment approach for stimulus similarity changes conclusions regarding
substitution by bupropion. Further research will be needed to identify whether such differences
may be related to different facets of nicotine dependence and/or its treatment.
INTRODUCTION
In the United States, tobacco consumption is responsible for approximately one fifth of all
deaths [ca. 443,000 deaths per year (CDC, 2008)]. The United States currently loses more
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than $193 billion on healthcare and loss of productivity associated with the use of tobacco
products (CDC, 2008). Although 70% of smokers express a desire to quit, only 40% of all
smokers make a serious quit attempt each year. Without treatment, of those that quit, only
about 5% will remain abstinent for a year (CDC, 2008; Lemmens et al, 2008). Behavioral
and/or pharmacological interventions increase this success rate 3 to 6 fold depending on the
study (Lemmens et al., 2008). Although these interventions improve outcomes, relapse rates
remain high. If more successful treatment strategies are to be designed, then we need to
better understand the basic mechanisms underlying this tenacious habit.
When nicotine, the primary addictive constituent of tobacco, is ingested, it produces a
complex internal stimulus composed of many neurobiological elements. This drug stimulus
can acquire control over behavior (Murray and Bevins, 2011). In the laboratory, human
participants will learn to discriminate nicotine from saline and place poker chips in a
particular pile when under the influence of nicotine (Perkins et al., 1999). Similarly, rats
responding, such as pressing a left lever 25 times to receive a food pellet, will come under
the control of the nicotine stimulus (Colpaert, 1999; Solinas et al., 2006; Wooters et al.,
2009). These stimulus effects, and the acquired appetitive properties conferred by the
learning history, likely contribute to the development of nicotine dependence and the
tenacity of habitual tobacco use (Bevins and Palmatier, 2004; Bevins and Murray, 2011).
We have been studying interoceptive conditioning involving nicotine using a discriminated
goal-tracking (DGT) task. In the DGT task, rats have the nicotine stimulus reliably paired
with access to a non-drug appetitive stimulus (e.g., liquid sucrose); in the absence of
nicotine (i.e., saline), the reinforcer is not available. After a brief period of training, a goal-
tracking response comes to be differentially evoked by the nicotine stimulus. Goal-tracking
refers to approach behavior to a location where the reinforcer has occurred in the past
(Boakes, 1977; Farwell and Ayres, 1979). Previous research has shown that this acquired
appetitive behavior controlled by the nicotine stimulus does not reflect state-dependent
learning (Bevins et al., 2007; Murray and Bevins, 2011), cannot be attributed to a non-
associative or stimulant effect of nicotine (Besheer et al., 2004; Murray et al., 2009; Reichel
et al., 2007; Wilkinson et al., 2006), and follows many postulates of Pavlovian conditioning
(Bevins and Murray, 2011; Murray et al., 2009).
One such postulate, extinction, refers to the non-reinforced presentation of a stimulus that
had been previously paired with a reinforcer; responding evoked by the stimulus tends to
decrease over non-reinforced presentations (Pavlov, 1927; Wasserman and Miller, 1997).
Some forms of extinction likely occur as a natural consequence of quitting smoking. That is,
during abstinence, some stimuli previously associated with smoking (e.g., sight of a
cigarette or package, smell of coffee, etc.) occur in the absence of nicotine. Of course,
exposure to smoking-related stimuli can facilitate relapse and, in principle, this effect should
be alleviated to some extent with cue-exposure (extinction) therapies (Conklin, 2006; Lee et
al., 2007).
In part, the difficulty in quitting that tobacco users often experience may result from the
appetitive learning history with the nicotine stimulus. This learning history with the nicotine
stimulus remains intact when one quits without the aid of a pharmacotherapy and may
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contribute to how quickly a lapse in smoking cessation leads to return of pre-cessation
smoking patterns (Bevins and Palmatier, 2004; CDC, 2008). Pharmacotherapies such as
bupropion or nicotine replacement may not only serve to alleviate withdrawal symptoms,
such as depressed mood and cognitive deficits, they may also facilitate decoupling of the
reinforcers in the environment from the stimulus effects of nicotine (i.e., extinction). In the
DGT task, non-reinforced presentations of the nicotine stimulus produce a systematic
decrease in the goal-tracking conditioned response (Besheer et al., 2004; Murray et al.,
2009; Wilkinson et al., 2006). This effect occurs even when the dose of nicotine in
extinction is lower than the training dose (Polewan et al., 2013).
Of primary interest in the present report is the finding that the acquired appetitive response
controlled by the nicotine stimulus can be blunted by non-reinforced presentations of other
ligands that share stimulus effects with nicotine (Reichel et al., 2010). More specifically, rats
were first trained with nicotine as the conditioned stimulus in the DGT task. Then, in the
subsequent extinction phase, a ligand that shares stimulus effects with nicotine [e.g.,
nornicotine or varenicline (Chantix®)] was used as the stimulus for extinction. The
effectiveness of this extinction history was assessed in a challenge test where all rats were
tested with the training dose of nicotine. Reichel et al. (2010) observed that the goal-tracking
response in rats that had received either nornicotine or varenicline in extinction was
diminished relative to controls; albeit less effective than receiving nicotine in extinction.
This diminished responding, referred to as “transfer of extinction learning”, reflects
generalization of the non-reinforcement history with the “nicotine-like” ligand back to the
original excitatory nicotine stimulus.
Although varenicline will partially substitute for nicotine in extinction, we have not
examined the other United States FDA approved non-nicotine pharmacotherapy for smoking
cessation—bupropion (Zyban®). Accordingly, one goal of the present study was to
determine whether extinction learning involving the bupropion stimulus would transfer back
to the nicotine stimulus as evidenced by weaker responding relative to controls. Experiment
1 tested whether extinction (6 sessions) with bupropion as a substitution ligand would
transfer back to the nicotine stimulus. The low dose bupropion (20 mg/kg) in this
experiment did not substitute for the nicotine stimulus in the transfer test. Therefore,
Experiment 2 tested whether prolonged extinction (up to 24 daily sessions) with 20 mg/kg
bupropion would deepen extinction and hence enhance transfer of extinction back to
nicotine. Another potential approach to deepening extinction is re-extinction. Re-extinction
refers to a second extinction attempt after the previously extinguished stimulus has been
retrained (see later for more detail). Experiment 3 examined re-extinction learning with the
bupropion stimulus.
MATERIALS AND METHODS
Animals
There were 187 young adult male Sprague-Dawley rats (275–299 g upon arrival from
Harlan; Indianapolis, IN, USA) used in the present experiments. Rats were housed
individually in clear polycarbonate cages (48.3 × 26.7 × 20.3 cm) lined with wood shavings.
The temperature- and humidity-controlled colony room was kept on a 12-h light/dark
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schedule. All experiments were conducted during the light cycle. Water was freely available
in the home cage and access to chow (Harlan Teklad Rodent Diet; Harlan, USA) was
restricted to maintain rats at 85% of their free-feeding body weight. Four weeks into the
study, this 85% target weight was increased by 2 g. All experimental protocols were
approved by the University of Nebraska-Lincoln Animal Care and Use Committee.
Apparatus
All experiments were conducted in commercially available conditioning chambers
(ENV-008CT; Med Associates, Inc.; St. Albans, VT, USA) measuring 30.5 × 24.1 × 21 cm
(l × w × h) enclosed in a sound and light attenuating cubicle equipped with an exhaust fan.
Each chamber had aluminum sidewalls, metal rod floors with polycarbonate front, back, and
ceiling. A recessed receptacle (5.2 × 5.2 × 3.8 cm; l × w × d) was centered on one of the
sidewalls. A dipper arm when raised provided access to 0.1 ml of 26% (w/v) sucrose in the
receptacle. Access to the dipper was monitored by an infrared beam mounted 1.2 cm into the
receptacle and 3 cm above the rod floor. Beam breaks for dipper entries were recorded using
Med Associates interface and software (Med-PC for Windows, version IV).
Drugs
Bupropion hydrochloride (Toronto Research Chemicals; Toronto, ON, Canada) and (–)-
nicotine hydrogen tartrate (Sigma; St. Louis, MO, USA) were dissolved in 0.9% saline. The
pH of nicotine was adjusted to 7.0 ± 0.2 with a dilute NaOH solution. All drugs were
administered at 1 ml/kg. Bupropion was administered intraperitoneal (IP); nicotine was
injected subcutaneous (SC). Injection routes, drug doses, and time between injection and
onset of behavioral assessment were based on previous reports from our laboratory (Besheer
et al., 1999; Bevins et al., 2001; Murray and Bevins, 2007; Wilkinson et al., 2010). Nicotine
dose is reported as base, whereas bupropion doses are reported as salt.
Behavioral Procedures
Experiment 1: 6 Days of Extinction with Bupropion
Preliminaries: Rats (n=48) were acclimated to the colony for 5 days and then handled for a
minimum of 2 min on each of three consecutive days before the start of the experiment. To
attenuate initial locomotor suppressing effects of nicotine (Besheer et al., 2004; Bevins et
al., 2001), all rats received nicotine (0.4 mg/kg; SC) on each of the three days before the
start of the training phase.
Discrimination Training: For each of the 32 daily training sessions, rats were injected SC
with either nicotine (0.4 mg/kg) or saline 5 min before placement in the chamber for a 20-
min session. Each rat received a unique order of 16 nicotine and 16 saline sessions with the
restriction that no more than two of the same session type (nicotine or saline) occurred in a
row. Sucrose was available only during nicotine sessions. Access to sucrose was initiated
between 124 to 152 s from the start of the session. There were 36 separate 4-sec deliveries
of sucrose per nicotine session. Time between sucrose deliveries ranged from 4 to 80 s
(mean = 25 s). On intermixed saline sessions, sucrose was in the dipper well, but the dipper
cup was never raised (i.e., no sucrose access). Discrimination training, as well as the
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remaining phases of the experiment, was conducted in a dark chamber and there were no
other programmed cues of any kind during the session.
Extinction: Following this training, rats were assigned to one of four groups (n=12 per
group) with the condition that groups responding throughout the training did not differ
statistically, as confirmed by two-way (Group × Session) mixed factor analysis of variance
(ANOVA). For the 6 daily extinction sessions, rats received saline, 0.4 mg/kg nicotine, 20
mg/kg bupropion, or 30 mg/kg bupropion before placement in the chamber for a 20-min
session without any sucrose deliveries. Bupropion was administered 15 min before the
session; nicotine was administered 5 min before the session. To control for any possible time
and/or route of administration effects, all rats received counterbalanced saline injections. For
example, rats that had nicotine as the extinction ligand received an IP saline injection 15 min
before the session onset. In contrast, rats that had bupropion as the extinction ligand
received saline (SC) 5 min before the session.
Transfer of Extinction Tests: Following extinction, all rats were tested for transfer of
extinction learning back to the nicotine training stimulus. On 4 separate test days, rats in all
groups were injected with 0.4 mg/kg nicotine and placed in the chamber 5 min later for a 20-
min test session. A saline injection was also 15 min before chamber placement so that time
of injection did not serve as signal for the test ligand.
Experiment 2: Extensive Extinction with 20 mg/kg Bupropion—Following
discrimination training, which was identical to Experiment 1, rats (n=60) were assigned to
one of five groups with the condition that group performance did not differ statistically in
the training phase. Depending on group assignment (n=12 per group), rats were injected
with 20 mg/kg bupropion for 24, 12, 6, 3, or 0 (saline control) consecutive days before the
transfer of extinction tests. Rats that received less than 24 extinction sessions with
bupropion had the remainder of the 24 sessions as non-reinforced saline sessions. For
example, rats assigned to receive 6 extinction sessions with bupropion were first given 18
consecutive saline sessions. This protocol controls for handling, number of injections, and
chamber exposure. Thus, only the number of extinction sessions with the bupropion
stimulus varied between groups. The transfer tests followed the extinction phase by 24 h and
were identical to those in Experiment 1. That is, all rats were challenged with the training
dose of nicotine before each 20-min test.
Experiment 3: Re-extinction with Bupropion—Unless otherwise noted, the
procedural details were identical to Experiment 1. Rats (n=79) first had excitatory
conditioning with the nicotine stimulus. Following this training, rats were assigned to
receive saline, nicotine (0.4 mg/kg), 20 mg/kg bupropion, or 30 mg/kg bupropion for 6
consecutive extinction sessions (see Figure 1A for timeline). Following 24 h after the last
day of extinction, rats had one transfer of extinction test with the training dose of nicotine.
All rats then had 8 daily sessions (4 nicotine and 4 saline) of retraining the discrimination. In
our experience, 8 retraining sessions is more than sufficient to reestablish stable conditioned
responding to the nicotine stimulus. Following retraining, rats were assigned to one of 7
groups (n=10 to 12). Figure 1B depicts group assignment. The name of each group refers to
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the ligand used in each extinction phase. For example, rats in the NIC/NIC group were
extinguished and re-extinguished with nicotine. Rats in the SAL/30BUP group had saline in
the first extinction phase and 30 mg/kg bupropion in the second extinction phase. The re-
extinction phase was procedurally the same as extinction. Rats were injected with their
assigned ligand at the prescribed injection-to-placement interval for each of the 6 sessions.
Following 24 h after the last re-extinction session, there were 4 daily transfer of extinction
tests with the 0.4 mg/kg training dose of nicotine.
Dependent Measures
For discrimination training, the primary dependent measure was the rate of dipper entries
per second before the first sucrose delivery or an equivalent time for saline sessions. A rate
measure was required as the time to the initial sucrose delivery varies across nicotine
sessions. Further, using dipper entries before the initial sucrose delivery kept the measure of
conditioning from being contaminated by sucrose access. Because sucrose was not available
in the extinction, the re-extinction, or the transfer test phase, we used total dipper entries in
the 20-min session as the dependent measure.
Statistical Analyses
An omnibus analysis of variance (ANOVA) preceded planned comparisons. Higher-order
interactions were further analyzed by two-way ANOVAs and followed, if necessary, by
limited Tukey’s HSD post-hoc tests (p<0.05). For discrimination training, a Drug (nicotine
vs, saline) × Session within-subjects repeated measures ANOVA was performed. For
Experiments 1 and 3, the effect of ligand on extinction used 4 × 6 (Drug × Session) repeated
measures ANOVA. The effect of re-extinction drug on re-extinction was analyzed using this
analytical approach. To examine the effect of extinction history on transfer of extinction
tests, a one-way ANOVA on the first transfer test of Experiment 3, or two-way repeated
measures ANOVAs (Drug × Session) were performed for Experiment 1 and second transfer
test of Experiment 3. Given the nature of the design of Experiment 2, an omnibus
Group×Session repeated measures ANOVA in the extinction phase was not employed.
Rather, corresponding session data from the extinction phase of Experiment 2 were analyzed
using planned LSD mean pairwise comparisons restricted to contrasting each test value with
corresponding vehicle control session.
RESULTS
Experiment 1: 6 Days of Extinction with Bupropion
Discrimination Training—For the training phase, an omnibus ANOVA revealed a
significant main effect of Drug [i.e., nicotine vs. saline; F(1,94)=1282.83, p<0.001] and
Session [1–16; F(15,1410)=21.12, p<0.001], as well as a significant Drug × Session
interaction [F(15,1410)=35.88, p<0.001]. Responding on the first nicotine session was lower
than saline; this switched, with nicotine-evoked responding higher than saline for sessions 4
to 16 (Figure 2A).
Extinction—In extinction, there was a main effect of Drug [i.e., saline, nicotine, 20 or 30
mg/kg bupropion; F(3,263)=10.97, p<0.001]; the main effect of Session [F(5,263)=2.00,
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p=0.07] and Drug × Session interaction (F<1) were not significant. For the main effect
Drug, the saline group had less dipper entries than nicotine or either bupropion group
(Figure 2B). Notably, there were no significant differences in the magnitude of the
conditioned response during extinction between the bupropion and nicotine groups. This
data pattern suggests that bupropion across repeated 20-min extinction sessions fully
substituted for the interoceptive stimulus effects of nicotine.
Transfer of Extinction Tests—There was a significant main effect of Drug
[F(3,175)=11.07, p<0.001] and Session [F(3,175)=5.14, p<0.01], but no Drug × Session
interaction (F<1). For the main effect of Drug, rats previously treated with nicotine or 30
mg/kg bupropion in the extinction phase had lower levels of responding than rats that had
saline or 20 mg/kg bupropion (Figure 2C). This outcome indicates that extinction learning
with 30 mg/kg bupropion was comparable to extinction with the nicotine stimulus in the
transfer test. Notably, extinction learning with 20 mg/kg did not generalize back to the
nicotine stimulus.
Experiment 2: More Extensive Extinction with 20 mg/kg Bupropion
Discrimination Training—As in Experiment 1, there was a significant main effect of
Drug [F(1,118)=202.88, p<0.001], a main effect of Session [F(15,1770)=20.99, p<0.001],
and a significant Drug × Session interaction [F(15,1770)=33.97, p<0.001]. Dipper entries on
nicotine sessions 1 and 2 were lower than saline; this pattern reversed (i.e., elevated
goaltracking on nicotine sessions) from session 4 to 16 (data not shown).
Extinction—Rats that had 24 extinction sessions with 20 mg/kg bupropion had greater
goal-tracking than saline controls on extinction sessions 1 to 3, 5, and 10; responding was
comparable to saline thereafter (see Figure 3A and 3B for all extinction data). Rats that had
12 extinction sessions with bupropion had higher responding than saline controls on
extinction sessions 1 to 3, 5, 6, 9, 10, and 12. Rats that had 6 days of bupropion treatment
differed from saline controls on sessions 1 to 4, and 6 of extinction. Rats that had 3 days of
extinction with bupropion had higher responding than controls on all three sessions.
Transfer of Extinction Tests—For the nicotine transfer test, there was a main effect of
Session [F(3,165)=14.5, p<0.001] indicating decreased responding across tests. However,
there was no main effect of Group or Group × Session interaction [Fs<1; Figure 3C].
Although there is a mean tendency for less responding after 24 extinction sessions, the
results of this analysis indicate that even extended extinction did not facilitate transfer of
extinction learning with 20 mg/kg bupropion.
Experiment 3: Re-extinction with Bupropion
Discrimination Training—There was a main effect of Drug [F(1,2506)=1591.92,
p<0.001], a main effect of Session [F(15,2506)=26.03, p<0.001], and a significant Drug ×
Session interaction [F(15,2506)=47.38, p<0.001]. Dipper entries on nicotine sessions were
higher than saline on sessions 4 to 16 (data not shown).
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Initial Extinction—There was a main effect of Group [F(3,448)=100.86, p<0.001] and of
Session [F(5,448)=5.46, p<0.001], as well as a Group × Session interaction
[F(15,448)=3.09, p<0.001]. Overall, dipper entries were higher in the nicotine and
bupropion (20 and 30 mg/kg) groups than in saline controls (Figure 4). The group treated
with 30 mg/kg bupropion had lower responding relative to nicotine and 20 mg/kg bupropion
only on the first extinction session. Saline controls were lower that nicotine and 20 mg/kg
bupropion across all the sessions, and from 30 mg/kg on sessions 2 to 6. Thus, bupropion
appears to substitute fully for the nicotine stimulus across repeated extinction sessions.
Transfer Test 1—Following initial 6 days of extinction, we tested the generalization of
the non-reinforcement history with bupropion to the nicotine training stimulus (0.4 mg/kg
nicotine). On this transfer test, there was a main effect of Group [F(3,121)=7.89, p<0.001].
Saline controls had higher dipper entries than rats that had nicotine in the initial extinction
phase (Figure 4). The tendency for conditioned responding to be reduced in the groups that
had bupropion in the extinction phase did not reach criterion for statistical significance.
Retraining of Discrimination—The differences in initial extinction histories did not
affect reacquisition (data not shown). There was no main effect of Group (F<1) and
interactions that included Group were not significant (Fs≤1.5). Responding on all nicotine
retraining sessions was higher than saline sessions.
Re-extinction—Table 1 shows all significant main effect group comparisons for re-
extinction. Overall, there was a main effect of Group [F(6,360)=41.45, p<0.001] and Session
[F(5,360)=4.59, p<0.001], as well as a Group × Session interaction [F(30,360)=1.83,
p<0.01]. Using separate planned comparisons, we first asked whether re-extinction differed
from initial extinction. Overall, responding in the re-extinction phase for group NIC/NIC
was lower than group SAL/NIC that had extinction with nicotine the first time [main effect
of Group; F(1,105)=9.70, p<0.01; Figure 5A]. Similarly, responding in re-extinction for
group 20BUP/20BUP was lower than group SAL/20BUP [main effect of Group;
F(1,100)=41.39, p<0.001; Figure 5B]. This data pattern indicates that extinction learning in
the initial phase was not completely lost by retraining with nicotine. A similar effect was not
seen between group 30BUP/30BUP and group SAL/30BUP (Figure 5C).
The next planned analyses examined differences between groups that had an extinction
history with a ligand only once (i.e., SAL/20BUP, SAL/30BUP, SAL/NIC); group
SAL/SAL serves as a benchmark and was included in the analyses. There was a significant
main effect of Group [F(3,195)=55.59, p<0.001] and of Session [F(5,195)=2.50, p<0.05];
the interaction was also significant [F(15,195)=1.85, p<0.05; Figure 5D]. Overall,
responding in SAL/NIC group was higher than SAL/SAL. Both SAL/20BUP and SAL/
30BUP displayed responding comparable to SAL/NIC; responding in these groups differed
from SAL/SAL. This substitution pattern replicated the full substitution between bupropion
and nicotine seen in Experiment 1. The interaction was driven by differences in responding
observed on sessions 1 to 4. Specifically, responding in group SAL/NIC differed from the
SAL/SAL on sessions 1 to 3, while responding in SAL/20BUP group was higher than
SAL/SAL on sessions 1 to 4. Further, on session 1, responding in SAL/20BUP group was
higher than SAL/30BUP.
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Planned analyses of extinction curves among groups that had re-extinguished with the same
ligand (i.e., 20BUP/20BUP, 30BUP/30BUP, or NIC/NIC) revealed a main effect of Group
[F(3,215)=61.87, p<0.001] and a Group × Session interaction [F(15,215)=2.82, p<0.001;
Figure 5E]. The main effect of Session was not significant [F(5,215)=1.55, p=0.17]. Overall,
responding in NIC/NIC group was significantly higher than SAL/SAL, 20BUP/20BUP, and
30BUP/30BUP. The pattern of responding in groups 20BUP/20BUP and 30BUP/30BUP
now suggests only partial substitution for the nicotine stimulus. That is, overall levels of
goal-tracking in those groups were higher than SAL/SAL but lower than NIC/NIC. This
partial substitution is in contrast to the full substitution seen with single extinction in this
study (Figure 5D) and Experiment 1 (Figure 2B). As for the significant Group × Session
interaction, responding in NIC/NIC group was higher than SAL/SAL on sessions 1 to 6.
Responding in 20BUP/20BUP was higher than SAL/SAL on sessions 1 and 3. Responding
in 30BUP/30BUP was higher than SAL/SAL on sessions 2, 3, 4, 6 and lower than NIC/NIC
on session 1.
Transfer Test 2—These planned comparisons were designed to elucidate to what degree
the extinction or re-extinction with bupropion generalizes back to the nicotine stimulus. All
significant main effect group comparisons for the second transfer test are listed in the Table
1. An omnibus ANOVA revealed a main effect of Group [F(6,216)=12.23, p<0.001] and of
Session [F(3,216)=3.48, p<0.05], as well as a Group × Session interaction [F(18,216)=2.12,
p<0.01]. With separate planned comparisons, we first asked whether or not rats with single
extinction histories differ from those with re-extinction histories in their responding evoked
by the nicotine stimulus. Overall, responding in group SAL/NIC was higher than NIC/NIC
[main effect of Group; F(1,63)=14.60, p<0.001; Figure 6A]. Similarly, responding in SAL/
20BUP was higher than 20BUP/20BUP [F(1,59)=13.29, p<0.001; Figure 6B]. Transfer test
performance of groups NIC/NIC and 20BUP/20BUP suggests that a history of retraining
and re-extinction enhances generalization of extinction learning across the ligands. A similar
outcome did not occur with 30 mg/kg bupropion. Overall responding in SAL/30BUP group
was lower than 30BUP/30BUP group [F(1,63)=10.53, p<0.01; Figure 6C]. The
Group×Session interactions were not significant in these planned comparisons.
A separate analysis of groups with single extinction histories (SAL/20BUP, SAL/30BUP,
SAL/NIC, and SAL/SAL control) revealed main effects of Group [F(3,117)=7.45, p<0.001]
and Session [F(3,117)=2.92, p<0.05], and a significant interactions [F(9,117)=2.10, p<0.05].
Overall (see Figure 6D for all comparisons), responding in SAL/SAL group was higher than
NIC/NIC. Response pattern in SAL/30BUP group indicates generalization of extinction to
the nicotine stimulus; goal-tracking differed from group SAL/SAL, but not from SAL/NIC.
Similar transfer of extinction was not seen in group SAL/20BUP with goal-tracking in that
group lower than SAL/NIC and not different from the SAL/SAL control. This pattern of
substitution replicates the findings from the transfer tests in Experiment 1 (recall Figure 2C).
The interaction was driven by the differences on session 1 where responding in group SAL/
30BUP and group SAL/NIC was lower than group SAL/SAL.
Analysis of transfer test 2 data, with groups that had extinction and re-extinction with the
same ligand (20BUP/20BUP, 20BUP/30BUP, NIC/NIC, and SAL/SAL), revealed
significant main effects of Group [F(3,129)=16.91, p<0.001] and Session [F(3,129)=3.00,
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p<0.05], and a significant interaction [F(9,129)=3.34, p<0.01]. Overall responding (the main
effect) in NIC/NIC group was lower than in SAL/SAL, 20BUP/20BUP, and 30BUP/30BUP
groups (see Figure 6E). The overall pattern of responding suggests that reextinction with 20
mg/kg bupropion enhanced generalization of extinction learning with responding evoked by
the nicotine stimulus partially weakened; goal-tracking in 20BUP/20BUP group was higher
than in NIC/NIC and lower than in SAL/SAL groups. Recall that transfer of extinction with
20 mg/kg bupropion did not occur without this reextinction (Figure 4). Group 30BUP/
30BUP did not show substitution for nicotine as responding in this group was higher than
NIC/NIC and did not differ from SAL/SAL; this is in contrast to a full substitution of SAL/
30BUP for SAL/NIC seen in re-extinction transfer tests including groups with single
extinction histories (Figure 6D). The Group×Session interaction was driven by the
differences observed on session 1 and 2. Specifically, responding in groups 20BUP/20BUP
and 30BUP/30BUP was similar to NIC/NIC on the session 1, yet differed from SAL/SAL;
full substitution for nicotine stimulus. Further, responding in SAL/SAL group on sessions 1–
2, and responding in 20BUP/20BUP and 30BUP/30BUP on session 2, was higher than
responding in NIC/NIC group.
DISCUSSION
Internal or interoceptive stimuli can be powerful modulators of behavior. Their control of
behavior can be modified by experiences (i.e., learning processes). This learning regarding
interoceptive stimuli is involved in such important health issues as pain, aging and
cognition, eating disorders (Craig, 2003; Kanoski, 2012), and drug addiction (Bevins and
Palmatier, 2004; Bevins et al., 2012). We have been using the discriminated goal-tracking
task to study the behavioral and neural processes of interoceptive conditioning involving the
nicotine stimulus (Bevins and Murray, 2011; Bevins et al., 2012; Charntikov et al., 2012).
The research in the present report extends previous studies showing bupropion substitution
for the interoceptive stimulus effects of nicotine (Besheer et al., 2004; Wiley et al., 2002;
Wilkinson et al., 2010; Young and Glennon, 2002). These earlier studies use testing
protocols designed to minimize learning, such as very brief tests (e.g., 4 min) without the
reinforcer [see Bevins et al. (2012) for more on this issue]. An alternative approach to
studying the similarity of interoceptive stimuli is to test whether the ligand of interest will
evoke substitution-like responding in prolonged (i.e., 20 min) and repeated extinction
sessions. This approach essentially asks the extent to which the test ligand will continue to
evoke the acquired behavior even though the reinforcer is withheld (see Reichel et al., 2010;
Wilkinson et al., 2010). The current experiment further extends past research on bupropion
substitution for nicotine by examining whether a learning history of non-reinforcement with
bupropion would generalize back to the nicotine stimulus. Across the three experiments in
this report, we found that (i) bupropion (both 20 and 30 mg/kg doses) fully substitutes for
the interoceptive effect of nicotine during repeated 20-min extinction sessions, (ii) the extent
of substitution in the repeated extinction sessions did not necessarily predict performance in
the transfer test, (iii) transfer of extinction was not seen with 20 mg/kg bupropion even after
increasing the number of extinction session from 6 to 24, (iv) there was evidence that what
was learned in the initial extinction phase was retained in the re-extinction phase for nicotine
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and bupropion, and (v) re-extinction with bupropion dose dependently affected performance
to nicotine stimulus in the subsequent transfer tests.
Using prolonged and repeated extinction testing, that allows for the opportunity to learn
about non-reinforcement, we found that 20 and 30 mg/kg bupropion evoked goal-tracking
that was comparable to nicotine. This full substitution of bupropion for the nicotine stimulus
differs somewhat from previous findings from our laboratory using brief substitution tests.
For example, Besheer et al. (2004) found partial substitution with 20 mg/kg bupropion in a
2-min test. Wilkinson et al. (2010), however, used 4-min tests and found full substitution by
bupropion at 20 mg/kg, but 30 mg/kg dose evoked only partial substitution. This comparison
suggests that using repeated and more prolonged extinction test sessions within the
discriminated goal-tracking task can provide different answers regarding stimulus
substitution. This suggestion is consistent with previous research using this approach
(Polewan et al., 2013; Reichel et al., 2010). For example, using the brief 4-min testing
protocol, the α4β2 nicotinic acetylcholine receptor agonist ABT-418 (0.6 mg/kg) evoked
goal-tracking comparable to nicotine (Reichel et al., 2010). However, in repeated extinction
sessions, like those used here, ABT-418 only evoked a partial conditioned response in the
first session, and no substitution in the subsequent 5 extinction session.
As detailed earlier, another way of assessing stimulus similarity among ligands is to assess
whether extinction learning generalizes to the training stimulus. Interestingly, in the present
report, the extent of substitution in the repeated extinction sessions did not necessarily
predict performance in the transfer test. For example, 20 and 30 mg/kg bupropion evoked
goal-tracking comparable to nicotine across repeated extinction sessions; a result that
suggests full substitution for the nicotine stimulus. In Experiment 1, full substitution in the
extinction phase by bupropion did not translate into full substitution in the transfer test.
During the transfer test, responding in rats that had 20 mg/kg bupropion in extinction had
slightly attenuated goal-tracking, but did not differ from controls that did not receive
extinction. In contrast, the extinction learning with 30 mg/kg fully generalized back to the
nicotine stimulus in this initial study. However, in Experiment 3, and in our unpublished
studies, transfer of extinction learning with this higher dose of bupropion appears to be more
like the 20 mg/kg dose; a mean tendency toward decreased responding when challenged
with nicotine, but not meeting cutoff for significance. We believe further investigation of
these dissociations between brief substitution tests, repeated extinction tests, and transfer
tests will provide a better understanding of the drugs under investigation (cf. Bevins et al.,
2012). For example, what other factors besides stimulus similarity produce the responding
evoked by bupropion in the extinction phase? Do these other factors play a role in the
effectiveness of bupropion as a smoking cessation drug? Are there ways to enhance
extinction learning to bupropion in a manner that would reliably attenuate conditioned
responding controlled by the nicotine stimulus in the transfer test? Re-extinction seems to be
one answer to this latter question, but increased number of extinction trials does not seem to
work, at least with the 20 mg/kg dose of bupropion.
Extinction involves new inhibitory learning that competes with previous excitatory stimulus-
reward association (Bouton, 1988, 2000; Rescorla, 2001) -- nicotine–sucrose in our case.
One of the ways to improve or deepen extinction learning is to increase the number of
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opportunities to learn about non-reinforcement in the extinction phase. (Bouton and Sunsay,
2003; Denniston et al., 2003; Mackintosh, 1975; Pearce and Hall, 1980; Rescorla and
Wagner, 1972). Thus, we expected that increasing the number of extinction sessions with 20
mg/kg bupropion would deepen the inhibitory association with the bupropion stimulus and
non-reinforcement. If there is sufficient overlap between the bupropion stimulus and the
nicotine stimulus, then strengthening this association should translate into a blunted
response when challenged with nicotine in the transfer test. This approach did not work with
the 20 mg/kg bupropion stimulus. In Experiment 2, rats extinguished with 20 mg/kg
bupropion, up to 24 separate occasions (versus 6 in Experiment 1), still did not differ from
controls that did not receive any extinction history with bupropion. Future research could try
alternative approaches to initial extinction that might deepen extinction. Perhaps extinction
that was more spaced such as a session every other day may be more effective. Some
published studies with more typical exteroceptive stimuli presented repeatedly within a
single session show that temporal spacing does affect extinction learning (e.g., Moody et al.,
2006). What if extinction was conducted more like a discrimination procedure with
intervening saline days? Whether or not access to sucrose was provided on these intermixed
saline sessions would also be of interest.
There is a very limited literature on re-extinction, even with exteroceptive stimuli (cf.
Langton and Richardson, 2009; Leslie and Norwood, 2013; Quirk, 2002). The paucity of
research is surprising given the interest in extinction and cue-exposure approaches to so
many health issues including drug addiction (Conklin and Tiffany, 2002; Conklin, 2006;
Ferguson and Shiffman, 2009; O’Brien et al., 1990). Past research with the discriminated
goal-tracking task has examined reacquisition following extinction with a nicotine stimulus
(Besheer et al., 2004; Murray and Bevins, 2007). That research has never examined
reextinction with the nicotine stimulus, or any other ligand for that matter. We found that the
pattern of conditioned responding in extinction changes in re-extinction with the very same
stimulus. For example, re-extinction with 20 mg/kg bupropion evoked significantly lower
responding relative to rats receiving extinction with this same dose for the first time (see
Figure 5B). This outcome suggests that something learned in the initial extinction phase
remained, at least partly, intact following the brief retraining of the discrimination. Notably,
a similar effect was observed in rats re-extinguished with nicotine (Figure 5A), but not with
30 mg/kg bupropion (Figure 5C). The literature with exteroceptive stimuli examining
retention of extinction learning following retraining is mixed. For example, Quirk (2002)
found that re-extinction of fear conditioning controlled by a tone in rats was faster in
comparison to initial extinction. Others in the fear conditioning field have not shown this
effect (Langton and Richardson, 2009; Leslie and Norwood, 2013).
Across the three experiments, extinction with 20 mg/kg bupropion in the initial extinction
phase did not affect subsequent responding to the nicotine stimulus. In contrast, re-
extinction with 20 mg/kg bupropion resulted in significantly lower conditioned responding
evoked by the nicotine stimulus (see Figure 6B). Re-extinction reflects 6 additional sessions
in which the reinforcer is withheld while the rat is on bupropion. However, this doubling of
the extinction sessions seems an unlikely account for diminished responding to the nicotine
stimulus following re-extinction. Namely, neither 12 nor 24 consecutive extinction sessions
with 20 mg/kg bupropion were sufficient to decrease the subsequent responding evoked by
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the nicotine stimulus (Experiment 2; Figure 3C). It seems that this reacquisition and re-
extinction experience impacted how learning regarding non-reinforcement with 20 mg/kg
bupropion generalized back to the nicotine stimulus.
The suggestion that re-extinction can engage different processes than initial extinction is
consistent with research elucidating neural processes underlying re-extinction using a
Pavlovian fear conditioning task. For example, Langton and Richardson (2008) first paired
illumination of a light with a foot shock in rats. In a subsequent extinction phase, the light
was presented without a foot shock. In this initial extinction phase, administration of the
partial NMDA agonist D-cycloserine accelerated extinction of fear evoked by the light.
These same rats were then retrained with the light–shock pairings and then subjected again
to extinction. In this re-extinction phase, the rate at which conditioned responding to light
(i.e., freezing) decreased was not affected by the D-cycloserine. This finding suggests that
learning in the initial extinction phase is NMDA-dependent, whereas learning in the
reextinction is NMDA-independent; this conclusion has been supported further in a series of
follow-up experiments (Langton and Richardson, 2010, 2009).
These studies by Langton and Richardson (2008, 2009, 2010), combined with the re-
extinction study in the present report, support the notion that re-extinction engages distinct
neural networks from extinction that may be of import to how conditioned responding is
expressed and what factors may diminish control of this responding. Of interest in future
work with the nicotine stimulus will be to identify the behavioral and neural processes that
may differ between extinction and re-extinction of interoceptive conditioning. For example,
what is the role of NMDA in the extinction and re-extinction with nicotine as an
interoceptive stimulus? Are there distinct neural networks that are differentially involved in
the extinction and re-extinction with nicotine as an interoceptive stimulus? Answers to these
questions may provide a better understanding of relapse in chronic human smokers who on
average initiate 7 lifetime quit attempts with about 40% of smokers making a serious
attempt to quit each year (CDC, 2005; Colby et al, 2011). These quit attempts, sometime
done cold turkey and sometimes with the aid of a pharmacotherapy or cognitive/behavioral
intervention, reflect potential learning opportunities. Because nicotine is a complex stimulus
able to function as a primary reinforcer and an interoceptive stimulus susceptible to
modification by learning, it is critical to take these effects into consideration and design
therapies that address, and periodically reassess, nicotine’s multifaceted control of patient
behavior.
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Highlights
• We examined bupropion substitution for the nicotine stimulus in extinction
• Bupropion substituted for nicotine during repeated extinction
• Substitution in extinction did not predict performance in the transfer test
• Pattern of substitution differed in extinction and re-extinction
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Fig. 1.
Graphical representation of procedures employed in Experiment 3 (A) Experimental time
line and (B) Group, extinction, and re-extinction ligand assignments.
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Fig. 2.
Data from all three phases of Experiment 1. (A) A mean (±SEM) number of dipper entries
per second during 2 min prior to initial sucrose or equivalent in timing no reward
presentations. *Denotes sessions with significant differences between saline and nicotine
evoked responding. (B) A mean (±SEM) number of total dipper entries during the six
extinction sessions. *Denotes overall group differences. (C) A mean (±SEM) number of
total dipper entries during four nicotine transfer tests. *Denotes overall group differences.
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Fig. 3.
Data from extinction and nicotine transfer phases of Experiment 2. (A) A mean (±SEM)
number of total dipper entries during extinction sessions with bupropion and saline control.
*Denotes group means significantly different from a corresponding session of saline
controls. (B) A mean (±SEM) number of total dipper entries during extinction sessions with
saline prior to extinction with bupropion; includes saline control. (C) A mean (±SEM)
number of total dipper entries during four nicotine transfer tests.
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Fig. 4.
A mean (±SEM) number of total dipper entries during extinction and transfer test sessions of
Experiment 3. *Denotes overall group differences during extinction and transfer test 1.
Charntikov et al. Page 21
Neuropharmacology. Author manuscript; available in PMC 2015 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 5.
A mean (±SEM) number of total dipper entries during re-extinction sessions of Experiment
3. Each panel represents data from each of separate planned analyses: (A–C) comparison of
groups receiving extinction ligand in either one or both of extinction phases, (D) comparison
of groups with single extinction histories, (E) comparison of groups receiving extinction
ligand in both extinction and re-extinction phases of the experiment. *Denotes overall group
differences. ‡Denotes differences from a corresponding SAL/SAL session. #Denotes
difference from a corresponding SAL/NIC session. abIndicates wherea is different fromb.
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Fig. 6.
A mean (±SEM) number of total dipper entries during transfer test 2 of Experiment 3. Each
panel represents data from each of separate planned analyses: (A–C) comparison of groups
receiving extinction ligand in either one or both of extinction phases, (D) comparison of
groups with single extinction histories, (E) comparison of groups receiving extinction ligand
in both extinction and re-extinction phases of the experiment. *Denotes overall group
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differences. ‡Denotes differences from a corresponding SAL/SAL session. #Denotes
difference from a corresponding SAL/NIC or a NIC/NIC sessions.
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